- ►hivandhepatitis.com [PDF] EB Keeffe, DT Dieterich, SHB Han, IM Jacobson … - Clinical Gastroenterology and Hepatology, 2008 - Elsevier Chronic HBV infection is an important public health problem worldwide and in the
United States. A treatment algorithm for the management of this disease,
published previously by a panel of US hepatologists, has been revised on ... Cited by 65 - Related articles - All 81 versions
JL Dienstag - N Engl J Med, 2008 - fundapoyarte.org From the Gastrointestinal Unit (Medical Services), Massachusetts General Hos-
pital; and the Department of Medicine and Office of the Dean for Medical Edu-
cation, Harvard Medical School — both in Boston. Address reprint requests ... Cited by 55 - Related articles - View as HTML - All 10 versions
- ►nih.gov JM Pawlotsky, G Dusheiko, A Hatzakis, D Lau, … - Gastroenterology, 2008 - Elsevier Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing
viral replication to the lowest possible level, and thereby to halt the
progression of liver disease and prevent the onset of complications. Two ... Cited by 52 - Related articles - All 38 versions
P Marcellin, TT Chang, SG Lim, W Sievert, M … - Hepatology, 2008 - interscience.wiley.com Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic
hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in
significant histological, virological, serological, and biochemical ... Cited by 35 - Related articles - All 4 versions
F Zoulim, R Perrillo - Journal of hepatology, 2008 - Elsevier This article summarizes the current state of antiviral therapy of hepatitis B
with special attention given to areas that remain controversial or poorly
defined. Strict adherence to liver association practice guidelines may ... Cited by 32 - Related articles - All 35 versions
MJ Tong, C Hsien, L Hsu, HE Sun, LM Blatt - Hepatology, 2008 - karaciger.org Current guidelines for treatment of chronic hepatitis B include hepatitis B e
antigen (HBeAg) status, levels of hepatitis B virus (HBV) DNA, and serum alanine
aminotransferase (ALT) values in the setting of either chronic hepatitis or ... Cited by 19 - Related articles - View as HTML - All 3 versions
Y Yuan, UH Iloeje, J Hay, S Saab - Journal of Managed Care Pharmacy, 2008 - amcp.org ABSTRACT BACKGROUND: As new treatment options for chronic hepatitis B virus
(HBV) become available, evaluations of cost-effectiveness become important.
Entecavir is a deoxyguanine nucleoside analogue approved by the US Food and ... Cited by 12 - Related articles - View as HTML - BL Direct - All 5 versions
Y Ngo, Y Benhamou, V Thibault, P Ingiliz, M … - PLoS One, 2008 - pubmedcentral.nih.gov The combination of transaminases (ALT), biopsy, HBeAg and viral load have
classically defined the inactive status of carriers of chronic hepatitis B. The
use of FibroTest (FT) and ActiTest (AT), biomarkers of fibrosis and ... Cited by 12 - Related articles - All 5 versions
- ►fundapoyarte.org [PDF] CL Lai, MF Yuen - The New England Journal of Medicine, 2008 - nejm.highwire.org The hepatitis B virus (HBV) causes chronic in- fection in approximately 400
million people in the world. Most carriers of chronic HBV, including Asians,
Africans, and a proportion of persons in Mediterranean countries, acquire ... Cited by 10 - Related articles - All 4 versions
I Trieste - Am J Gastroenterol, 2008 - giorgiobedogni.it Giorgio Bedogni, MD,1 Lucia Miglioli, MD,2 Flora Masutti, MD,1 Silvia Ferri,
MD,3 Anna Castiglione, MD,1 Marco Lenzi, MD,3 Lory Saveria Croc`e, MD,1
Alessandro Granito, MD,3 Claudio Tiribelli, MD, Ph.D.,1,4 and Stefano ... Cited by 8 - Related articles - View as HTML - All 8 versions
